CABA Cabaletta Bio
- 10.670
- -0.250-2.29%
Cabaletta Bio News
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright analyst Douglas Tsao maintains $Cabaletta Bio(CABA.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 37.0% and
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
Express News | HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target
Cabaletta Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 136.41% HC Wainwright & Co. → $30 Reiterates Buy → Buy 04/05/2024 294.01% Cantor Fitzgerald → $
Express News | Cabaletta Bio Inc : Jefferies Cuts Target Price to $31 From $36
Cabaletta Bio's Promising Clinical Advancements and Stable Financial Outlook Merit a Buy Rating
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results.Bolt Biotherapeutics posted a GAAP loss of 28 cent
William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than
Cabaletta Bio | 10-Q: Quarterly report
Cabaletta Bio Reveals Insights in Updated Corporate Presentation
Express News | Cabaletta Bio Expects That Its Cash, Cash Equivalents And Short-term Investments Of $223.8M As Of March 31, 2024, Will Enable It To Fund Its Operating Plan Into The First Half Of 2026
Express News | Cabaletta Bio Q1 2024 GAAP EPS $(0.51) Misses $(0.47) Estimate
Cabaletta Bio Had Cash, Cash Equivalents and Short-Term Investments of $223.8M at March 31 >CABA
Cabaletta Bio Had Cash, Cash Equivalents and Short-Term Investments of $223.8M at March 31 >CABA
Express News | Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Cabaletta Bio Q1 Operating Expenses USD 28.031 Million
Express News | Cabaletta Bio Q1 Income From Operations USD -28.031 Million
Press Release: Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update -- No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patie
Cabaletta Bio 1Q Loss/Shr 51c >CABA
Cabaletta Bio 1Q Loss/Shr 51c >CABA
Analysis
Price Target
No Data
